Literature DB >> 21177746

Donor cell origin of multiple myeloma occurring after allogeneic haematopoietic stem cell transplantation in a patient with refractory anaemia with ring sideroblast.

Young-Il Kim1, Hye-Ran Kim, Myung-Geun Shin, Young-Jin Lee, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening complication after solid organ and haematopoietic stem cell transplantation. A 40-year-old woman who was diagnosed as having refractory anaemia with ring sideroblast 6 years ago took an ABO mismatched, unrelated allogeneic haematopoietic stem cell transplantation (HSCT) from a 32-year-old healthy male donor. The bone marrow (BM) study was carried out because of progressing pancytopenia, serum biclonal gammopathy and a distorted ratio of serum level of free κ and λ light chain 138 days after HSCT. The BM examination showed an increased number of plasma cells (12% of total marrow cells) comprising mainly CD45-CD19-CD138+ malignant plasma cells with an immunoglobulin heavy-chain gene rearrangement. Conventional cytogenetics and molecular personal identification studies revealed that all BM cells were totally replaced by donor cells, thus indicating the donor cell origin of PTLD-multiple myeloma. The BM microenvironment of the recipient might be associated with the development of PTLD-multiple myeloma.

Entities:  

Mesh:

Year:  2010        PMID: 21177746     DOI: 10.1136/jcp.2010.084731

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

2.  Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?

Authors:  Sule Mine Bakanay; Esin Serbest; Klara Dalva; Isinsu Kuzu; Meral Beksac
Journal:  Case Rep Med       Date:  2012-06-28

3.  A 54-Year-Old Woman with Donor Cell Origin of Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of CML.

Authors:  Erika Maestas; Shikha Jain; Patrick Stiff
Journal:  Case Rep Hematol       Date:  2016-02-18

4.  Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML.

Authors:  Bita Fakhri; Mark Fiala; Michael Slade; Peter Westervelt; Armin Ghobadi
Journal:  Case Rep Hematol       Date:  2017-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.